Phase Ii Trial Of The Parp Inhibitor, Niraparib, In Brca1-Associated Protein 1 (Bap1) And Other Dna Damage Response (Ddr) Pathway Deficient Neoplasms Including Cholangiocarcinoma.

Thomas J. George,David L. DeRemer,Ji-Hyun Lee,Stephen Staal,Merry Jennifer Markham,Dennie V. Jones,Peter Joel Hosein,Karen Colleen Daily,Jonathan Alexander Chatzkel,Brian Hemendra Ramnaraign,Julia Lee Close,Martina Cathryn Murphy,Carmen Joseph Allegra,Sherise C. Rogers,Azka Ali,Robert A. Hromas

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 3|浏览4

暂无评分

摘要

TPS354Background: BRCA1-Associated Protein 1 (BAP1) is a critical regulator of the cell cycle, cellular differentiation, cell death, and DNA damage response. It also acts as a tumor suppressor. Pre...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要